146 related articles for article (PubMed ID: 8174795)
1. Viral inactivation vs biological activity.
Barrowcliffe TW
Dev Biol Stand; 1993; 81():125-35. PubMed ID: 8174795
[TBL] [Abstract][Full Text] [Related]
2. Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation.
Raut S; Di Giambattista M; Bevan SA; Hubbard AR; Barrowcliffe TW; Laub R
Thromb Haemost; 1998 Oct; 80(4):624-31. PubMed ID: 9798982
[TBL] [Abstract][Full Text] [Related]
3. At what stage should virus inactivation be carried out?
Dorner F; Barrett PN; Eibl J
Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
[TBL] [Abstract][Full Text] [Related]
4. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
5. Quality control in the development of coagulation factor concentrates.
Snape TJ
Dev Biol Stand; 1987; 67():141-7. PubMed ID: 3609474
[TBL] [Abstract][Full Text] [Related]
6. Theoretical considerations on viral inactivation or elimination.
Willkommen H; Löwer J
Dev Biol Stand; 1993; 81():109-16. PubMed ID: 8174793
[No Abstract] [Full Text] [Related]
7. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
[TBL] [Abstract][Full Text] [Related]
8. Chromatographic removal of viruses from plasma derivatives.
Burnouf T
Dev Biol Stand; 1993; 81():199-209. PubMed ID: 8174804
[TBL] [Abstract][Full Text] [Related]
9. Viral safety of solvent-detergent treated blood products.
Horowitz B; Prince AM; Horowitz MS; Watklevicz C
Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
[TBL] [Abstract][Full Text] [Related]
10. Considerations in performing virus spiking experiments and process validation studies.
Darling AJ
Dev Biol Stand; 1993; 81():221-9. PubMed ID: 8174806
[TBL] [Abstract][Full Text] [Related]
11. [No ELISA detectable alterations in immunogenicity following dry-hear treatment (72 hours at 80 degrees C) of FANHDI].
Bravo MI; Massot M; Jorquera JI
Sangre (Barc); 1999 Dec; 44(6):412-7. PubMed ID: 10822752
[TBL] [Abstract][Full Text] [Related]
12. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII.
Roberts PL; Dunkerley C; McAuley A; Winkelman L
Vox Sang; 2007 Jan; 92(1):56-63. PubMed ID: 17181591
[TBL] [Abstract][Full Text] [Related]
13. A solvent I detergent treated, pasteurised and highly purified factor VIII concentrate.
Schwinn H; Stadler M; Josic D; Bal F; Gehringer W; Nur I; Schütz R
Arzneimittelforschung; 1994 Feb; 44(2):188-91. PubMed ID: 8147954
[TBL] [Abstract][Full Text] [Related]
14. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of parvovirus B19 during STIM-4 vapor heat treatment of three coagulation factor concentrates.
Berting A; Modrof J; Unger U; Gessner M; Klotz A; Poelsler G; Kreil TR
Transfusion; 2008 Jun; 48(6):1220-6. PubMed ID: 18410254
[TBL] [Abstract][Full Text] [Related]
16. Viral safety of coagulation factor concentrates.
Mannucci PM
Dev Biol Stand; 1993; 81():253-9. PubMed ID: 8174811
[No Abstract] [Full Text] [Related]
17. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
[TBL] [Abstract][Full Text] [Related]
18. Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4.
Schneider B; Fryer JF; Oldenburg J; Brackmann HH; Baylis SA; Eis-Hübinger AM
Haemophilia; 2008 Sep; 14(5):978-86. PubMed ID: 18565125
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
[TBL] [Abstract][Full Text] [Related]
20. Theoretical and technical concerns in inactivation/elimination of viruses in plasma derivatives.
Hilfenhaus J; Niedrig M; Nowak T
Dev Biol Stand; 1993; 81():117-23. PubMed ID: 8174794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
